23 October 2024
Read More3 October 2024
Read More26 September 2024
Read MoreWe are a family of strong 800+ people including 470+ professionals working from 14 locations across India.
We have a rich heritage and enduring legacy which are pivotal in shaping trust, excellence, and unparalleled legal expertise, thus building a strong reputation and a trusted brand.
Read MoreWe started in 1985 in a single room set up by the two founders with no prior experience of working in a law firm. Both the founders had outstanding academic records and focused on their deep understanding of the law to form the foundation of the firm.
Integrity, Knowledge and Passion are the principles that resonate with every member of our LKS family and the work that we do. These values drive us to build a community of legally sound professionals and well-serviced clients.
Everything we have accomplished over the last four decades is a result of our unique way of thinking which is deeply influenced by our core values and principles that define us.
Read MoreWe and our professionals consistently garner appreciation for the quality of our services and the depth of our legal expertise. This consistent acknowledgment serves as a testament to our unwavering commitment to exceed expectations.
The article in this issue of IPR Amicus examines a recent decision of the Delhi High Court, where the High Court has redefined the boundaries of permissible claim amendments for overcoming the objections on non-patentability especially Section 3(i) of the Patents Act, 1970, without jeopardizing the requirements of Section 59. The primary focus of this article is on the interpretation of Section 3(i) and Section 59 of the Act as provided by the High Court. Considering the facts of the case and the High Court’s analysis of claim amendments, the authors conclude by stating that the Applicants can file claim amendments to overcome the non-patentability objections, such as Section 3(i) per the Indian Patent Law, keeping in view the boundaries of Section 58 and 59. They also note that this decision also clarifies that product claims cannot and must not be objected under Section 3(i) of the Act, since the said Section only refers to claims directed to a process.
The article in this issue of IPR Amicus, while exploring the subject, analyses various case...
The decision focused on two pivotal issues - whether the enhanced bioavailability data could be...
Get access to our latest newsletters, articles and events:
Scan the QR code to get in
touch with us